End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy—Modified N7 Regimen with Dinutuximab Beta. - Lu, Evelyn R.; Hoo, Calvin P. L.; Cheung, Ho Ming; Wong, I. W. C.; Fung, K. F. Kevin; Chang, Sylvia L. Y.; Lee, Anselm C. W.; Fu, Eric C. H.; Ku, Dennis T. L.; Yau, Jeffrey P. W.; Shing, Matthew M. K.; Mak, Christy Y. K.; et al. (Cancers, 2026)